OBJECTIVE: To determine the incidence of and predisposing risk factors for lactic acidosis in HIV-infected patients on antiretroviral drugs in South Africa. DESIGN: Observational case series. SETTING: Sinikithemba HIV Clinic, McCord Hospital, Durban. SUBJECTS: Eight hundred and ninety-one HIV-positive patients on highly active antiretroviral therapy (HAART) during an 18-month period commencing in January 2004. MEASUREMENTS AND RESULTS: Fourteen cases of lactic acidosis (incidence rate of 19 (95% confidence interval (CI): 9-29) cases per 1,000 person-years of treatment) were reported. All cases were female, with a median age of 36 years and a median weight of 81 kg. The median time on HAART before developing lactic acidosis was 7.5 months and the median peak lactate level was 9.3 mmol/l. All cases were on stavudine (d4T), lamivudine (3TC) and 1 non-NRTI. The case mortality rate was 29% (4 patients). CONCLUSIONS: The incidence rate is higher than reported in studies in developed countries. This may be due to d4T, which is recommended as a first-line antiretroviral drug in South Africa. This implication raises the question whether it is an appropriate drug in first-line treatment of patients with predisposing risk factors such as female gender and being overweight.
OBJECTIVE: To determine the incidence of and predisposing risk factors for lactic acidosis in HIV-infectedpatients on antiretroviral drugs in South Africa. DESIGN: Observational case series. SETTING:Sinikithemba HIV Clinic, McCord Hospital, Durban. SUBJECTS: Eight hundred and ninety-one HIV-positive patients on highly active antiretroviral therapy (HAART) during an 18-month period commencing in January 2004. MEASUREMENTS AND RESULTS: Fourteen cases of lactic acidosis (incidence rate of 19 (95% confidence interval (CI): 9-29) cases per 1,000 person-years of treatment) were reported. All cases were female, with a median age of 36 years and a median weight of 81 kg. The median time on HAART before developing lactic acidosis was 7.5 months and the median peak lactate level was 9.3 mmol/l. All cases were on stavudine (d4T), lamivudine (3TC) and 1 non-NRTI. The case mortality rate was 29% (4 patients). CONCLUSIONS: The incidence rate is higher than reported in studies in developed countries. This may be due to d4T, which is recommended as a first-line antiretroviral drug in South Africa. This implication raises the question whether it is an appropriate drug in first-line treatment of patients with predisposing risk factors such as female gender and being overweight.
Authors: Christopher J Hoffmann; Katherine L Fielding; Salome Charalambous; Mark S Sulkowski; Craig Innes; Chloe L Thio; Richard E Chaisson; Gavin J Churchyard; Alison D Grant Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: C William Wester; Svetlana K Eden; Bryan E Shepherd; Hermann Bussmann; Vladimir Novitsky; David C Samuels; Sher L Hendrickson; Cheryl A Winkler; Stephen J O'Brien; Max Essex; Richard T D'Aquila; Victor DeGruttola; Richard G Marlink Journal: AIDS Res Hum Retroviruses Date: 2012-06-01 Impact factor: 2.205
Authors: Charlotte Schutz; Andrew Boulle; Dave Stead; Kevin Rebe; Meg Osler; Graeme Meintjes Journal: AIDS Res Ther Date: 2010-05-26 Impact factor: 2.250
Authors: Christopher J Hoffmann; Salome Charalambous; Katherine L Fielding; Craig Innes; Richard E Chaisson; Alison D Grant; Gavin J Churchyard Journal: AIDS Date: 2009-08-24 Impact factor: 4.177
Authors: Lynn T Matthews; Janet Giddy; Musie Ghebremichael; Jane Hampton; Anthony J Guarino; Aba Ewusi; Emma Carver; Karen Axten; Meghan C Geary; Rajesh T Gandhi; David R Bangsberg Journal: PLoS One Date: 2011-04-11 Impact factor: 3.240